ArticleJournal of experimental & clinical cancer research : CR2026
GFAT2-mediated HSPD1 O-GlcNAcylation drives chemotherapy resistance in non-small cell lung cancer.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- O-GlcNAcylation at the tumor-immune interface: a metabolic post-translational code driving immune evasion and therapy resistance in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) patients often develop resistance to first-line etoposide/cisplatin (EP) chemotherapy. However, available studies only focus on single-agent resistance to either etoposide or cisplatin in NSCLC. Hence, a notable knowledge gap exists in terms of the mechanisms underlying multidrug resistance, particularly within a system that recapitulates EP resistance in NSCLC. This emphasizes an urgent need for new strategies to tackle this challenge.
methodsThis study established a chemotherapy-resistant xenograft mouse model that mimicked the clinical chemotherapy regimens used for patients with NSCLC and aimed to explore the molecular mechanisms that contribute to chemotherapy resistance in NSCLC. The key protein that regulates chemotherapy resistance in NSCLC were identified through proteomics and co-immunoprecipitation mass spectrometry (Co-IP/MS) analyses, and revealed its regulatory mechanisms.
resultsThis study identified glutamine-fructose-6-phosphate transaminase 2 (GFAT2,) as a key driver of resistance, upregulated in chemoresistant NSCLC cells. GFAT2 critically regulates the hexosamine biosynthetic pathway (HBP), enhancing uridine diphosphate-GlcNAc (UDP-GlcNAc) synthesis and overall O-GlcNAcylation. Specifically, GFAT2 augments O-GlcNAcylation of heat shock protein family D member 1 (HSPD1) at residue T320. This modification stabilizes HSPD1 by blocking its tripartite motif containing 21 (TRIM21)-mediated ubiquitination and degradation. Stabilized HSPD1 subsequently activates anti-apoptotic signaling, promoting cell survival during chemotherapy. Crucially, knockdown of either GFAT2 or HSPD1 restored chemosensitivity in models.
conclusionsThese findings elucidate the GFAT2/HSPD1 axis and O-GlcNAcylation as pivotal metabolic mechanisms underlying EP resistance, identifying them as promising therapeutic targets to overcome chemoresistance in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.